Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone QTc study in healthy Chinese subjects
NCT07263152Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hydronidone in hepatic fibrosis (6 arms), sponsored by Gyre Pharmaceuticals. Primary endpoint: Placebo-corrected change from baseline in QTc interval at 24 hours. Started Dec 2025; status: completed.
02
Drugs
hydronidone
03
Conditions
hepatic fibrosis
Beyond the preview
Go deeper on NCT07263152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263152.